J. David Enloe Jr.

David Enloe dark background_WebsitePresident and Chief Executive Officer

David Enloe brings nearly 20 years of executive management experience primarily in biotechnology, drug development and GMP Manufacturing.  Mr. Enloe joins Ajinomoto Althea Inc. after serving as Head of Lonza’s Viral Therapeutics Business Unit since August 2010. This new business unit was the result of Lonza’s acquisition of Vivante GMP Solutions, a company that Mr. Enloe founded in June, 2009 and where he served as President and CEO until its sale to Lonza AG.  Under Mr. Enloe’s leadership, the business experienced rapid expansion, with revenues increasing 500% over a three year period.  Preceding Vivante, Mr. Enloe spent 14 years with biotech company, Introgen Therapeutics, joining as its first employee in 1995 and spending several years as Senior Vice President and COO before ultimately being named President and CEO. In addition to helping start the company, Mr. Enloe was an integral part of taking Introgen through a successful IPO in 2000 as well as several other financial dealings.  In addition, Mr. Enloe oversaw several large corporate collaborations, as well as the filing of license applications with both the FDA and European regulatory authorities of Introgen’s lead product. Prior to Introgen, Mr. Enloe was in the energy sector in Southeast Asia, the Rocky Mountains, and Texas.  Mr. Enloe is a Certified Public Accountant and started his career in public accounting with Arthur Andersen & Co.    

Martha Demski

0051-Martha DSr. Vice President and Chief Financial Officer

Martha Demski has over 30 years of experience in the fields of finance and biotechnology. Most recently, Ms. Demski served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center (SKCC). She previously served for over 15 years as Vice President and Chief Financial Officer of Vical Incorporated where she was responsible for multiple private and public financings including an IPO. Ms. Demski also spent over 12 years in banking with Bank of America, most recently as Senior Vice President in their U.S. Trust Division. It was at Bank of America that she first became involved in the biotech industry in 1978 when she funded the first equipment leases for Hybritech Inc. and a multitude of other biotech companies that followed. Her Board activities include the Board of Chimerix Inc. where she currently serves as Chair of the Audit committee. At SKCC she previously served on the Board of Trustees as Chair of the Audit Committee and prior to that, Chair of the Governance and Nominating Committee. Additionally, Ms. Demski previously served on the Finance and Audit Committees of the San Diego Foundation. She holds an M.B.A with concentrations in finance and accounting from The University of Chicago Booth School of Business, and a B.A. from Michigan State University.

Chris Duffy

2012 Chris-DuffySr. Vice President of Operations

Chris Duffy serves as a Corporate VP and has line management responsibility for all contract manufacturing divisions including the Biologics Manufacturing group and the Fill & Finish operations. Mr. Duffy has been with the company since the year 2000, and has partnered with more than 100 Althea customers to meet their development and manufacturing goals. Mr. Duffy has broad experience in all phases of biologics manufacturing with extensive experience in the manufacturing of recombinant protein therapeutics, vaccines, and combination products. Mr. Duffy has over 26 years of experience managing biopharmaceutical and sterile manufacturing operations. Prior to joining Althea he held management positions in Product Development and Manufacturing at The Immune Response Corporation where he managed development and manufacturing activities associated with the company’s HIV therapeutic vaccine, and cancer vaccine products.